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Abstract
Background: Dental caries is one of the primary causes of tooth loss among adults. It is estimated to affect a
majority of Americans aged 55 and older, with a disproportionately higher burden in disadvantaged populations.
Although a number of treatments are currently in use for caries prevention in adults, evidence for their efficacy
and effectiveness is limited.
Methods/Design: The Prevention of Adult Caries Study (PACS) is a multicenter, placebo-controlled, double-blind,
randomized clinical trial of the efficacy of a chlorhexidine (10% w/v) dental coating in preventing adult caries.
Participants (n = 983) were recruited from four different dental delivery systems serving four diverse communities,
including one American Indian population, and were randomized to receive either chlorhexidine or a placebo
treatment. The primary outcome is the net caries increment (including non-cavitated lesions) from baseline to 13
months of follow-up. A cost-effectiveness analysis also will be considered.
Discussion: This new dental treatment, if efficacious and approved for use by the Food and Drug Administration
(FDA), would become a new in-office, anti-microbial agent for the prevention of adult caries in the United States.
Trial Registration Number: NCT00357877.
Background
Although children are the primary recipients of caries-
prevention programs in the United States (US), a recent
meta-analysis concluded that older adults experience
caries at the same or even higher rates [1]. Indeed, den-
tal caries is one of the primary causes of tooth loss
among adults [2-4], and is estimated to affect a majority
of Americans aged 55 and older [5]. Root caries in parti-
cular is one of the most common chronic infectious dis-
eases of midlife. Among Americans aged 45-64, root
caries is more prevalent (at 35%) [6] than chronic joint
symptoms (32%), hypertension (32%), arthritis (29%),
symptoms of mental illness (14%), heart disease (13%),
and diabetes (10%) [7]. Data from a largely employed
population with dental insurance found that mean
annual spending on adult dental care peaks between
ages 55 and 64, at about $700 per capita, and that car-
ies-related treatment accounts for about half of these
expenditures [8].
Adult caries can be particularly devastating in disad-
vantaged populations, such as the uninsured and certain
racial and ethnic minority groups [5]. One subgroup
that is particularly affected by dental caries is American
Indians. Based on data from the Indian Health Service’s
1999 oral health survey [9], 68% of 19-year-old Ameri-
can Indians have experienced caries, compared to 24%
of non-American-Indian 15-19-year-olds. Currently only
a b o u th a l fo fA m e r i c a n s( a n dj u s t1i n5o v e ra g e6 5 )
have dental insurance [10,11]. While the literature on
the impact of dental insurance on dental health is
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any medium, provided the original work is properly cited.limited, it is clear that the uninsured have a higher level
of edentulism (27% vs. 18.3% among insured) [12], a
higher number of untreated caries [13], and a lower
likelihood of visiting the dentist than the insured
[14,15]. When they do see the dentist, the uninsured are
more likely to receive a filling or extraction, or other
acute care, and are somewhat less likely to receive pre-
ventive services.
Although several practices are recommended to pre-
vent adult caries, a 2001 National Institutes of Health
(NIH) consensus panel concluded that the evidence base
for adult caries prevention is limited [16]. Everyone
should be advised to floss daily and use fluoridated
toothpaste 2-3 times per day. Adjunctive treatments
may be used, including in-office fluoride gels, profes-
sionally applied fluoride varnish, or home use of pre-
scription (5000 ppm) topical fluoride [17-19].
Chlorhexidine is an antimicrobial that may be an
effective adjunctive treatment for caries prevention. To
date, chlorhexidine rinse (0.12% w/v) has been approved
for use to reduce gingivitis, but not for caries preven-
tion. Chlorhexidine rinse, when used in an alternating
sequence of daily use for one month, then weekly for
5 months, failed to reduce caries more than a placebo
(quinidine) rinse over 5 years in a randomized study of
1101 adults 65 years and older [20]. In addition, contin-
ual use of chlorhexidine rinse may stain teeth.
Two placebo-controlled trials of the efficacy of a
chlorhexidine (10% w/v) dental coating applied by a
dental hygienist or dentist to prevent caries were
reported in 2000 [21,22]. Possible therapeutic advantages
of this formulation include a much higher chlorhexidine
concentration and longer contact time with the tooth
surface, which should intensify the anti-cariogenic
effects of chlorhexidine. In addition, in-office application
avoids patient compliance issues.
The first study enrolled 240 adults with xerostomia
aged 40-80 with an elevated risk of dental caries [21].
Participants were randomly assigned to active treatment
or to one of two control conditions (either a sham treat-
ment that contained quinine hydrochloride to mimic the
bitter taste of chlorhexidine or a placebo control) and
followed for 13 months, with four initial weekly treat-
ments followed by a fifth treatment at six months. Rela-
tive to placebo, the active treatment group had a 24.5%
greater reduction in combined root and coronal caries
increment (p = 0.03), a 40.8% reduction in root caries
increment (p = 0.02), and a 14.4% reduction in coronal
caries increment (p = 0.06). Although caries increment
scores also were reduced for the active treatment rela-
tive to the sham groups (13.8%, 32.5%, and 2.2%), these
reductions were not statistically significant (potentially
because of the antimicrobial properties of the sham
agent, quinine hydrochloride).
The second study enrolled 1,240 economically disad-
vantaged adolescents aged 11-13 years with a history of
decay and an elevated level of Streptococcus mutans
(250,000 cfu/mL). Participants were randomly assigned
to one of four arms: active drug, a placebo coating plus
best practice preventive care, a best practice preventive
care control condition, and a usual care control condi-
tion. All participants were followed for three years. Par-
ticipants in active and placebo-coating arms received
four initial weekly treatments, followed by additional
treatments at 12 and 24 months post- randomization.
Participants also received up to two additional treat-
ments each year, depending upon their level of salivary
S. mutans. An intent-to-treat analysis found no treat-
ment effect overall [22], but adherence to the study
treatment was poor, possibly affecting the results.
Unpublished secondary analysis in the per-protocol
sample found significant reduction in caries among girls
in the active treatment group compared to girls in con-
trol arms, as well as a gender difference in use of sugary
carbonated drinks, which may have reduced efficacy.
The current manuscript describes the protocol for the
Prevention of Adult Caries Study (PACS), which repre-
sents a third evaluation of the chlorhexidine dental coat-
ing and is being conducted as a “pivotal” study under
US Food and Drug Administration IND #45,466. PACS
is a randomized clinical trial being conducted over a
13-month observation period among adult participants
from four diverse communities in the United States,
each of which is served by distinctly different dental-
care delivery systems. Of note, PACS includes a large
uninsured population lacking regular access to dental
care, the western Navajo Nation and Hopi populations
in northern Arizona, and a large metropolitan commu-
nity without a fluoridated water supply. The primary
objectives of PACS are (1) to test the hypothesis that
the chlorhexidine dental coating, compared to a placebo
coating, will reduce dental caries increment in at-risk
adults from baseline to the 13-month follow-up visit;
and (2) to evaluate the cost and cost-effectiveness of
using the treatment from patient, program, and provider
perspectives.
Methods/Design
PACS is a multicenter, placebo-controlled, double-
blind, randomized clinical trial. Participating institu-
tions include the Kaiser Permanente Center for Health
Research in Portland, OR, which serves as the data
coordinating center, and four clinical centers: Tufts
University School of Dental Medicine (TUSDM) in
Boston, MA; the Tuba City Regional Health Care Cor-
poration (TCRHCC) on the Navajo Reservation in
northern Arizona; the Dental Service of Massachusetts
clinic in Southborough, MA (a part of Delta Dental of
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Care Program and Permanente Dental Associates in
Portland, OR. The study chair is located at Tufts Uni-
versity, and this center also is the location of the
microbiology laboratory. The study is sponsored by the
National Institute of Dental and Craniofacial Research
(NIDCR). The product manufacturer, CHX Technolo-
gies Inc., provides the study treatments, a Good Clini-
cal Practice (GCP) auditor (Schiff & Associates), and
some additional funding and quality assurance of the
product. Independent oversight of trial activities is pro-
v i d e db yaD a t aa n dS a f e t yM o n i t o r i n gB o a r d
appointed by the NIDCR. The study was approved by
the Institutional Review Boards of each participating
institution and by the FDA, and all participants pro-
vided written informed consent.
Study Population
The study population consists of individuals aged 18-
80 years, having 20 or more intact teeth and deemed
at increased risk of dental caries due to the presence
of one or more cavitated lesions at screening (Table 1).
We excluded participants for whom the study treat-
ment would be contraindicated, as well as participants
with health conditions that might affect the measure-
ment of study outcomes or their ability to successfully
complete the study. We targeted four communities
with varying fluoride exposure, dental reimbursement,
and overall risk of caries (Table 2). Financial incentives
varied by site and included cash incentives, reimburse-
ment of travel expenses and, for some individuals,
reimbursement for the cost of required restorative
care. Recruitment began in February, 2007 and con-
cluded in August, 2008.
All participants attended an initial screening visit to
assess eligibility. Eligible participants then received
necessary restorative care for all cavitated lesions prior
to returning for a randomization visit, at which time
additional baseline measurements (including a baseline
caries examination) were obtained. Individuals who still
had cavitated lesions at this point were referred back to
their treating dentist for further restorative care prior to
randomization, and the randomization visit was then
repeated.
Eligible participants were randomized to receive five
applications of either a chlorhexidine (10% w/v) or pla-
cebo dental coating over a seven-month interval.
A computerized randomization process confirmed parti-
cipant eligibility prior to issuing randomization assign-
ments. The latter were stratified by clinical center and
age and, within each strata, clustered in blocks of vary-
ing sizes. Participants and staff were blinded to treat-
ment assignment. Overall, we randomized 983
participants, close to our goal of 1000.
Table 1 Eligibility Criteria for PACS
Inclusion Criteria
* 18 years of age and older
* at least 20 intact natural teeth
* 2 or more lesions, one of which being a cavitated D2 or D3
* willing and able to provide informed consent
Exclusion Criteria
* pregnant or planning to become pregnant during the study (breastfeeding is permitted)
* use of fixed orthodontic appliances
* allergic to any of the ingredients of the study medication (chlorhexidine diacetate, Sumatra benzoin, alcohol, ammonio methacrylate copolymer
type B, or triethyl citrate)
* long-term antibiotic therapy (defined as taking an antibiotic – including low dose doxycycline (Periostat) - for 30 days or more in the past
3 months)
* currently taking any anti-fungal medication prescribed by a doctor or dentist
* a history of, or currently active, radiation therapy for cancers of the head or neck
* Sjögren’s syndrome
* advanced periodontitis and in the clinical judgment of the examiner, there is the likelihood the participant will not have 20 natural teeth at the
end of the study
* having ten or more teeth requiring restorative care at the time of the screening visit
* requires antibiotic prophylaxis for dental care
* remineralization therapy within one month of randomization (includes use of a fluoride varnish, 5000 ppm prescription fluoride toothpaste, a
0.12% chlorhexidine mouth rinse or gel, sodium fluoride mouth rinse, use of Xylitol products, by mouth, two or more times per day for four or more
days per week (excluding Trident)
* investigator discretion
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Treatment and data collection occurred at seven visits
during the study period (Table 3). We collected baseline
data and determined study eligibility at both the screen-
ing visit (SV) and randomization (V1) visits, which had
to occur within 4 months of each other. The first treat-
ment application occurred immediately following rando-
mization at the V1 visit. Three additional treatment
applications took place on a roughly weekly basis at the
second through fourth visits (V2- V4), followed by a
fifth and final treatment application seven months post-
randomization as part of the fifth visit (V5). The V5
visit also included a comprehensive outcome assess-
ment, together with a dental caries examination. Active
caries discovered at the V5 visit had to be restored
before the final treatment application. The final data-
collection visit (V6) was scheduled six months later, or
approximately 13 months post-randomization. This visit
included a comprehensive outcome assessment.
Participants at the Tufts clinical center also were
asked to take part in an optional substudy to assess the
effect of the study medication on resistant (S. mutans)
Table 2 Characteristics of PACS Clinical Center Populations
Study Center Recr quota Fluoride in water Dental reimbursement Est. caries prevalence versus US average
KP Portland 400 Partly Pre-paid managed care Same
Tufts 200 Yes Majority uninsured Same
Dental Service of MA, Southborough 200 Partly Primarily prepaid fee-for-service Same
Tuba City 200 Partly Access to free care Higher
Table 3 Schedule of Study Visits
SV (ts)V 1 ( t 0)V 2 ( t 1)V 3 ( t 2)V 4 ( t 3)V 5 ( t 4) V5a (t5)
Tufts only
V6 (t6) V6a (t7)
Tufts only
Target date ts+4 mos t0+7d t1+7 d t2+7 d t0+7 mos t0+10 mos t0+13 mos t0+19 mos
Allowable window 5-14 d 5-14 d 5-14 d ± 1 mo ± 1 mo ± 1 mo ± 1 mo
Eligibility questions X X
1
Exam for eligibility X
Demographic questions X
Informed consent X X
2
Dental restorations X
3 X
3 X
3
Pregnancy test X X X
Acidic drink consumption questions X X X X
Medical HX questions X X X
Oral Health HX questions X X
Randomization X
Tooth Surface Exam X X X
Coating Application X X X X X
Adverse Events questions X X X X X X X X
Medication questions X X X X X X X X X
Soft Tissue Exam X X X
Travel time/costs X X X
Care Utilization X
Candidiasis Lab Tracking X X X X X X X X X
Medication Price Survey X
Microbiology
Tufts only
X
4 X
4 X
4 X
5 X
5
1some eligibility information will be reassessed at V1.
2although not required, some study centers will use separate screening and randomization consent forms.
3following the screening visit (SV), any needed dental restorations are made prior to randomization (V1); additional restorative work, if needed, is performed
following the dental examinations at the V5 and V6 visits.
4testing for presence and level of S. mutans and C. albicans in a subset of patients at the Tufts clinical center.
5additional testing for S. mutans and C. albicans may occur at V6 and V6a depending on results of earlier tests.
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oral cavity. At each of the V1, V5, V5a, V6, and V6a vis-
its, selected participants provided a sample of stimulated
whole saliva for analyses of S. mutans sensitivity to
chlorhexidine and swabs of the right and left buccal
cheek mucosa for analyses of levels of C. albicans.S p e -
cimens were processed and analyzed by staff trained in
Good Laboratory Practice (GLP) at the microbiology
laboratory, which forwarded the results directly to the
data coordinating center. A total of 143 Tufts subjects
participated in this substudy.
Study Treatments
Study treatments were applied in-office by a dental
hygienist after a brief rubber cup prophylaxis with non-
fluoridated paste and scaling as needed. The coatings
were applied in two stages. In stage 1, the first coating
was applied to all tooth surfaces in a given quadrant of
the dentition. This was immediately followed by applica-
tion of the second coating (labeled Stage 2 on the vials)
to the same quadrant. The other three quadrants were
similarly treated and the coatings were air dried to
ensure proper hardening. All dental hygienists were
trained and certified in the proper application of the
coatings, and the entire process typically took 20 min-
utes to complete.
The stage 1 coating contains either chlorhexidine dia-
cetate suspended in a solution of Sumatra benzoin and
alcohol (the active treatment) or simply the Sumatra
benzoin and alcohol solution (the placebo treatment).
The second coating is a proprietary aqueous dispersion
of inert methacrylate approved for use by the FDA
under license K013671. This second coating lasts until it
is abraded by hard foods or is brushed from the teeth,
and is designed to give the chlorhexidine extended con-
tact time on the enamel.
The component medications used in both the Stage 1
and Stage 2 coatings were made under Good Manufac-
turing Practices[23] in an FDA-approved facility. All
treatments were packaged in a cardboard box containing
ten 2-mL capped amber glass vials (sufficient for all 5
study treatments). Each vial contained either 1 mL of
the Stage 1 coating or 1 mL of the Stage 2 coating. The
box was labeled for PACS and had a tamper-proof seal.
Stage 1 and Stage 2 vials had different colored labels,
and each vial was labeled for one of the five visits. The
treatment boxes were shipped overnight in refrigerated
packaging from the study pharmacist to the clinical cen-
ters; thermometers measured trans-shipment tempera-
tures. Upon receipt by the clinical centers, the treatment
boxes were immediately refrigerated. Studies have
demonstrated that the study treatments are stable at
room temperature for longer than three months and at
refrigerated temperatures for 30 months [24,25].
For participants in the active treatment arm, the mean
dose of chlorhexidine at each application visit was
expected to be approximately 33 mg (or 330 μL), so that
the cumulative mean dose for participants completing
all five applications was expected to be 165 mg.
Blinding of Study Treatments
Active and placebo-coating materials were packaged
identically and were distinguishable only by a numerical
label. Each box of treatment material contained a com-
plete supply of coatings for one person for the entire
study. Individual vials, together with the box in which
they were packaged, were affixed with the same label.
The sequence of numerical codes was random with
respect to likelihood that the package contained active
or placebo coating. Packing was done by a central facil-
ity under contract to CHX Technologies Inc., and active
and control boxes were prepared in separate production
runs using label identifications (IDs) supplied by the
data coordinating center. Independent verification of a
random sample of boxes was done to confirm that the
correct labels were assigned to the active and placebo
boxes.
Since prior studies have shown that differences in
taste or appearance between the study medication and
placebo were imperceptible when substances were
applied according to protocol, the likelihood of inadver-
tent unblinding of the patient, dental team, or other
clinic staff is minimal. In the unlikely event that staff do
become unblinded to the treatment status of a given
participant, the nature of the treatment allocation pro-
cess (as described above) means that the unblinding
would be a single event and that nothing could be
inferred about other participants’ treatment assignments.
Caries Examination and PACS Taxonomy
Caries were diagnosed visually by calibrated examiners
using a Community Periodontal Index of Treatment
Needs (CPITN) probe, an unblemished, non-magnifying
plane mirror; and standard dental operating light and
chair. Use of loupes was according to local practice. The
participants’ teeth were dried for five seconds with an
air/water syringe to better enable the examination of
tooth surfaces. At the request of the FDA, radiographs
were not used in diagnosis. Each central, lateral, and
cuspid tooth was deemed to have five coronal (including
the incisal) surfaces and four root surfaces. Examiners
made only one diagnostic judgment per tooth surface.
Two initial 4-day training and calibration sessions
were held at the two East Coast and West Coast sites
with a gold standard examiner. These were followed by
three recalibrations at roughly nine-month intervals.
The PACS taxonomy of adult dental caries used the
nomenclature of Pitts and Fyffe [26] that identifies
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(D1); lesions where the cavitation extends into, but not
through, the enamel (D2); and cavitated lesions that
involve the dentine (D3). (A modified taxonomy that
does not include the D3 score is used for root sur-
faces.) Each stage of decay involves different and dis-
tinct treatment implications in terms of cost, staff
time, and management. The D1, D2, and D3 designa-
tions are well understood by the community dentists
in all four PACS clinical centers. This taxonomy has
been used by Banting et al [21]. Papas et al.[27] and
Chesters et al. [28] to detect caries incidence. The
descriptors for the D1, D2, and D3 classifications in
PACS are adapted from the International Caries Detec-
tion and Assessment System (ICDAS) II [29], as shown
in Table 4. ICDAS II established objective clinical
signs that have been associated with severity levels of
dental caries (particularly the non-cavitated lesion) and
verified histologically, and uses a 2-digit numeric code
to classify each tooth site. The PACS taxonomy does
not make a number of distinctions that are in the
ICDAS II taxonomy. Instead, we have collapsed codes
as follows:
￿ The first digit codes 0, 1, 2 are collapsed into S
( s o u n do rs e a l e ds u r f a c e ) ,3 ,4 ,7 ,8a r ec o l l a p s e d
into F (filled), and 5, 6 are collapsed into C
(crowned)
￿ The second digit codes 1 and 2 were collapsed into
a single D1 code (uncavitated lesion). This was done
in recognition of the fact that it is difficult to train
dentists in detecting pre-clinical caries lesions.
￿ The second digit codes 3 and 4 were collapsed into
a single D2 code (cavitated lesion). This was done
because any degree of cavitation is generally
regarded as requiring intervention.
￿ The second digit codes 5 and 6 were collapsed into
a single D3 code (cavitated lesion into dentin).
For purposes of our primary analysis, calls that require
intervention are treated identically, so the D2 and D3
calls are collapsed into one category.
Primary Study Outcome
The primary study outcome is the net caries increment
(root and coronal surfaces combined) from baseline
(V1) to end-of-study (V6), scored as the number of
changes recorded from V1 to V6, including reversals.
This measure permits only one transition per tooth sur-
face (the V5 visit is used only to achieve a more efficient
multiple imputation, see below) and allows for theoreti-
cally plausible reversals (e.g., from D1 to sound) as well
as for implausible reversals that presumably result from
measurement error in one of the calls (e.g., D2 to
sound). Three additional measures of caries increment
(Table 5) will be included as secondary outcomes, to
give a comprehensive view of demineralization and
remineralization.
The net caries increment is computed as the sum,
across tooth surfaces, of transition scores (weights) asso-
ciated with 121 pre-defined transitions in tooth-surface
integrity (Table 6). Our preliminary weighting scheme,
as shown in the table, assigned a range of -2 to +2, with
transitions to a worse status receiving positive weights
Table 4 The PACS Taxonomy for Scoring Tooth Surfaces
PACS
code
Definition Corresponding ICDAS codes
S sound or pits-and-fissures sealant on sound surface 00, 10, 20
D1 non-cavitated lesion on otherwise sound or sealed surface 01, 02, 11, 12, 21, 22
D2 cavitated lesion on otherwise sound or sealed surface 03, 04, 05, 13, 14, 15, 16, 23, 24, 25
D3 cavitated lesion extending into the dentine on an otherwise sound or sealed surface 06, 26
F filling on otherwise sound or sealed surface 30, 40, 70, 80
FD1 non-cavitated lesion on surface already having a filling 31, 32, 41, 42, 71, 72, 81, 82
FD2 cavitated lesion on surface already having a filling 33, 34, 35, 43, 44, 45, 46, 73, 74, 75, 83, 84,
85
FD3 cavitated lesion extending into the dentine on a surface already having a filling 36, 76, 86
C full crown on surface otherwise sound or sealed 50, 60
CD1 non-cavitated lesion on surface already partially covered by a crown 51, 52, 61, 62
CD2 cavitated lesion on surface already partially covered by a crown 53, 54, 55, 63, 64, 65
CD3 cavitated lesion extending into the dentine on a surface already partially covered by a
crown
56, 66
Y unscorable or invisible surface (e.g., unexposed root) 96, 99
M surface on missing tooth 97, 98
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negative weights. Transitions that reflect no change (e.
g., D1 to D1), a change to treated status (e.g., D2 to F
or C), or to or from an unscorable status (Y or M) are
scored 0 and hence effectively excluded from analysis.
Remineralization from D1 to S is considered a plausible
reversal (-1), but not from D2 or D3. These tooth-sur-
face transitions are similar to those used by Chesters et
al. [28] in their fluoride-intervention study in young
adolescents. Like Chesters, we recognized that reversals
from cavitated lesions (bolded in Table 6) are not plau-
sible. After completion of bootstrapping analyses of a
caries increment dataset from another study (Gullion,
personal communication, 2009), we concluded that the
optimal way to handle unlikely or implausible transi-
t i o n si st oi g n o r et h e m( i . e . ,a s s i g naw e i g h to fz e r o ) .
Hence for our primary analysis the bolded values in
Table 6 will be ignored.
Other Study Measures
PACS assessed a number of safety measures and predic-
tors of caries increment at baseline.
Medical History
At V1, V5, and V6, participants completed a medical
history questionnaire indicating whether they had ever
been diagnosed or treated for a series of common medi-
cal conditions. An additional medical-eligibility ques-
tionnaire was asked at the screening visit.
Oral Health History
At V1 and V6, participants completed a brief question-
naire regarding their oral hygiene practices and dental
history.
Table 5 Analytical Models of Caries Increment
Model Description
Crude increment One event (change) per tooth surface is counted; no reversals are counted
Cumulative crude increment Multiple events are possible on a tooth surface; no reversals are counted
Net increment One event per tooth surface is counted; reversals are included
Cumulative net increment Multiple events per tooth surface are possible; reversals are included
Table 6 Transition Weighting Matrix
13-month Visit (V6)
Baseline
Visit (V1)
S D1 D2/D3 F FD1 FD2/FD3 C CD1 CD2/CD3 Y M
S 01 2 2 2 2 0 0 0 0 0
D1 -1 0 1 1 1 1 1 1 1 0 0
D2/D3 -2 -1 00 1 0 0 0 0 0 0
F- 2 - 1 0 01 2 01 2 0 0
FD1 -2 -2 -1 -1 0 1 1 1 1 0 0
FD2/FD3 -2 -2 -2 0 -1 00 0 00 0
C- 2 - 1 0 01 2 01 2 0 0
CD1 -2 -2 -1 -1 0 1 -1 0 1 0 0
CD2/CD3 -2 -2 -2 -2 -1 00 -1 00 0
Y 00 0 0 0 0 0 0 0 0 0
M 00 0 0 0 0 0 0 0 0 0
KEY
S = sound or pits-and-fissures sealant on sound surface (ICDAS codes 00,10,20).
D1 = non-cavitated lesion on otherwise sound or sealed surface (ICDAS codes 01,02,11,12,21,22).
D2/D3 = cavitated lesion on otherwise sound or sealed surface (ICDAS codes 03,04,05,06,13,14,15,16,23,24,25,26).
F = filling on otherwise sound or sealed surface (ICDAS codes 30,40,70,80).
FD1 = non-cavitated lesion on surface already having a filling (ICDAS codes 31,32,41,42,71,72,81,82).
FD2/FD3 = cavitated lesion on surface already having a filling (ICDAS codes 33, 34, 35, 36, 43, 44, 45, 46, 73, 74, 75, 76, 83, 84, 85, 86).
C = full crown on surface otherwise sound or sealed (ICDAS codes 50,60).
CD1 = non-cavitated lesion on surface already partially covered by a crown (ICDAS codes 51,52,61,62).
CD2/CD3 = cavitated lesion on surface already partially covered by a crown (ICDAS codes 53,54,55,56,63,64,65,66).
Y = unscorable or invisible surface (e.g., unexposed root) (ICDAS code 96,99).
M = surface on missing tooth (ICDAS code 97,98).
NOTE: some of the ICDAS codes listed may be specific to children, and are included only for completeness.
Vollmer et al. BMC Oral Health 2010, 10:23
http://www.biomedcentral.com/1472-6831/10/23
Page 7 of 11Soft Tissue Examination
Participants were examined for abnormalities of the oral
mucosa at V1, V5, and V6. An assessment for candidia-
sis was part of this examination. This assessment also
provides additional data to the microbiology substudy at
the Tufts clinical center.
Adverse Events
Starting at V1, participants were asked if they had
experienced any adverse events since the last visit. Addi-
tionally, at the treatment visits they were asked if they
had experienced any adverse events during the treat-
ment application. All serious adverse events (SAEs) were
immediately reported to the data-coordinating center,
the Project Office, the Study Chair and CHX Technolo-
gies Inc.; CHX Technologies Inc., in turn, notified the
FDA. The respective Institutional Review Boards of each
institution were also notified of adverse events.
Medication Use
Prescription medication use was tracked at each clinic
visit.
Demographic Information
Demographic information was collected as part of the
screening visit.
Pregnancy Status
Pregnant women and women who were planning to
c o n c e i v ed u r i n gt h ec o u r s eo ft h es t u d yw e r ee x c l u d e d
from participation. As a safety precaution, we confirmed
pregnancy status again at V5 and pregnant women did
not receive the final treatment application.
Acidic Drink Consumption
The consumption of acidic beverages can prematurely
erode the protective coating that was applied in stage 2
of the treatment application process. Participants were
asked to avoid drinking such beverages for three days
following treatment application, and we asked about
typical consumption of acidic beverages at the SV, V4,
V5, and V6 visits.
Intervention and Dental Care Costs
Program cost and cost-effectiveness analyses of the chlor-
hexidine coating will be assessed from patient and dental
plan perspectives [30]. Study staff conducted comprehen-
sive chart reviews to document all dental-care procedures
(CDT and local codes), procedure dates, billed claims,
amount paid by insurance, and insurance plan type for
encounters of study participants from the randomization
date to V6. Procedures and clinical service costs related
to SAEs were noted. We obtained clinical staff earnings
and clinic facility space to estimate provider training and
service delivery costs. We also included participant travel
time and costs for each clinical visit. These data will be
used to calculate the incremental net cost-effectiveness
per prevented caries increment of the intervention, com-
pared to placebo, for total and restoration-related dental
care expenditures. All costs will be expressed in a
reference year values (e.g., 2009 dollars). Expenditures
and outcomes occurring in month 13 will be discounted
to present value terms using a financial discount rate for
the medical-care service sector. Sensitivity analyses will
be conducted by varying key model inputs, and sub-
group analyses will be conducted if supported by the
data. We also conducted a price opinion survey at SV to
estimate patients’ willingness to pay for the service and
to support a cost-benefit analysis of the intervention [31].
TCRHCC participants receive free out-of-pocket care
and were excluded from the price survey.
Quality Control
In addition to being trained as caries examiners and
recorders, staff were centrally trained and certified in all
aspects of study operations, including questionnaire
administration, data entry, and application of the dental
coatings. Initial training occurred prior to the start of
randomization, with recertification occurring roughly
annually. The data-coordinating center monitored study
progress on an ongoing basis and generated regular trial
monitoring reports for review by the Steering Commit-
tee and the Data Safety Monitoring Board (DSMB).
The data-coordinating center used a secure, web-
based application for data entry and management. This
application incorporated real-time error checking and
quality assurance at the time of data entry and
prompted clinical center staff about potentially erro-
neous data during data entry. Additional “back-end”
checks were performed at the data-coordinating center.
In addition to the routine trial monitoring reports
generated by the data-coordinating center, Internet-
enabled reporting tools allowed authorized clinical cen-
ter staff to access additional reports and edit data on an
ad hoc basis. The data-coordinating center maintained
an electronic audit trail of all errors and error
resolutions.
PACS employed three types of site visit monitoring.
CHX Technologies Inc. conducted their own ongoing
monitoring. Schiff & Associates, an outside contractor
employed by CHX Technologies Inc., conducted three
independent monitoring visits at each clinical center–at
the beginning, middle, and end of the study. And finally,
the data-coordinating center conducted annual site visits
at each clinical center to review all aspects of quality
assurance, as defined in GCP [32].
Data Analysis
Analyses will be carried out in three samples. The
intent-to-treat (ITT) sample includes all randomized
participants, regardless of their adherence to the proto-
col, and classifies them according to their assigned treat-
ment group. The per-protocol sample consists of
participants who received all five applications of their
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treatment due to an adverse event, and did not deviate
from the protocol in any significant way that could have
affected the results. The safety sample consists of all
participants who received at least one study treatment.
These individuals are classified according to the actual
treatment received.
In order to include all randomized participants in the
ITT sample, we will use multiple imputation [33] to
impute missing caries examination data for the V6
(final) visit. The planned primary- outcome analysis will
be repeated in exactly the same way in each of the
imputed datasets, and the results combined using
Rubin’s [34] rules to produce the adjusted estimates and
statistics from which inferences will be drawn.
All statistical hypothesis tests will be performed with
two-sided type I error level of a=0.05. Interaction terms,
when included in the model (e.g., treatment-by-site),
will be assessed at a=0.10. No adjustment for multiple
testing is planned.
Primary Analysis
The primary efficacy analysis will be in the ITT popula-
tion, using analysis of covariance (ANCOVA), with
treatment group, clinical center, and examiner included
as categorical factors, and age and age-squared as con-
tinuous covariates. We will use rank-normalized net car-
ies increment scores in this analysis. We next will
evaluate whether an interaction exists between clinical
center and treatment and, if so, will estimate and test
center-specific treatment effects.
Secondary Analyses
Secondary Aim 1 We will test whether the effect of the
study medication differs within subgroups of the ITT
sample defined by: baseline decayed filled surfaces (DFS)
(median split), age (quartile groups), sex, and whether
these added covariates account for any clinical center
differences observed in the primary analysis.
Secondary Aim 2 We will evaluate incidence and incre-
ment of root and coronal caries in ITT participants by
age, socioeconomic status (education, income), dental
care setting (managed care, fee-for-service, etc.), and
health-related profile.
Secondary Aim 3 We will evaluate the impact that var-
ious models of caries increment and detection criteria
have on incidence and prevalence estimates of this most
common adult disease.
Secondary Aim 4 We will evaluate the effect of the
chlorhexidine (10% w/v) dental coating on resistant (S.
mutans) and opportunistic (C. albicans)i n f e c t i o n si n
t h eo r a lc a v i t yu s i n gt h es u b s e to fT u f t sp a r t i c i p a n t s
who are enrolled in the substudy.
Sensitivity Analyses
We will conduct a number of sensitivity analyses to
evaluate the robustness of thep r i m a r ye f f i c a c ya n a l y s i s
with respect to dropouts. In addition, the primary analy-
sis and all sensitivity analyses also will be performed in
the “per-protocol” sample.
Safety Analyses
Adverse events are classified using the MedDRA system
[35] and categorized by system/diagnosis group, severity,
relationship to study drug, action taken, and outcome.
Tabulations will be prepared showing number and per-
cent of subjects affected by an adverse event by treat-
ment group, seriousness, relatedness, and level of
cumulative exposure. The safety sample will be used for
this analysis.
Study Power
The power analysis takes account of the fact that we
plan to transform the observed caries- increment
s c o r e st oan o r m a ld i s t r i b u t i o n .W eu s e dad a t as i m u -
lation to determine what the impact of the transforma-
tion would be on the target effect size of 20%
reduction in net caries increment. The results of our
sample-size modeling, for varying effect sizes (Cohen’s
d, i.e., the ratio of mean difference to standard devia-
tion (SD)), are shown in Figure 1. The 20% target
effect size–expressed in rank-transformed units–is a d
of 0.225, at which 416 randomized per group yields a
power of 90%. The final target sample size of 1000
(500 per group) was deemed sufficient to provide ade-
quate power, given what we believe to be conservative
estimates of the effect size. These calculations do not
adjust for attrition since we plan to use multiple impu-
tation to obtain plausible replacement values for miss-
ing outcome measures.
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Figure 1 Sample size needed at varying effect sizes, using
normalized Poisson data.
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Adult dental caries is an expensive and chronic condi-
tion for many Americans, particularly certain minority
populations. PACS will provide useful data upon which
health-care policy makers and the dental community
can base decisions about whether to regularly include
the use of chlorhexidine coating to decrease or prevent
caries in adults. Our study will also analyze whether this
treatment can be used cost-effectively in a variety of set-
tings. The latter feature is particularly important given
the present state of knowledge, as few dental preventive
interventions have been appraised in terms of the eco-
nomic implications of their cost and their benefit.
The PACS population is highly diverse, both in terms
of the participants themselves and the dental delivery
systems from which they were recruited. In the study’s
Navajo and Hopi population in the Southwest, no out-
of-pocket direct payments are made by clients and
indemnity is explicitly assumed by the care system; in
the Pacific Northwest, the system is a not-for-profit den-
tal Health Maintenance Organization (HMO) catering
primarily to a white population that enjoys dental insur-
ance coverage through employers; and in Massachusetts,
the population is a mixed group served by a large dental
insurance carrier under various service schema, as well
as a study group recruited from Greater Boston by a
large university dental clinic serving a primarily unin-
sured population. While these groups will be pooled for
the primary analysis, secondary analyses will look at
treatment effects in selected subgroups.
We identified several priorities in creating the PACS
taxonomy for classifying dental caries. Priorities were
creating the taxonomy needed to recognize the growing
focus of dentistry on managing the non-cavitated lesion;
being primarily visual and requiring only gentle probing
to determine cavitation or the texture of the lesion base;
being easy to use and reproducible; being backwardly
compatible with conventional systems (e.g., Radike,
World Health Organization, NIDCR); and avoiding dis-
tinguishing between active and non-active lesions to
improve reliability of examiners. The resulting PACS
taxonomy allows for identification of root carious
lesions using a D1-D2 classif i c a t i o nw i t h i nt h eI C D A S
descriptors, as well as allowing for identifying caries
lesions associated with existing restorations for both
coronal and root caries. This system is being used suc-
cessfully in a separate, ongoing controlled clinical trial
of the chlorhexidine coating in four American Indian
communities.
Very few longitudinal studies of adult caries (1-4) have
been conducted over the last 10 years. The use of D1
lesions in this trial will test the expanded visual diagnos-
tic thresholds of ICDAS II in a large-scale randomized
clinical trial. It is theorized that the use of D1 lesions to
evaluate caries progression will permit shorter trials with
fewer participants and better subject retention. If suc-
cessful, such use will have implications for future dental
research evaluating dental therapies. The PACS study is
the first Phase III clinical trial to test this new model.
The need for new, cost-effective treatments to prevent
or hinder the progression of adult caries is considerable.
This study, together with other ongoing and completed
trials of a chlorhexidine coating, is an important contri-
bution to the establishment of sound evidence regarding
the efficacy of this promising caries-prevention
intervention.
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